Synonymer & Anagram | Engelska ordet GHRH

Exempel på hur man kan använda GHRH i en mening

• They can also cause overproduction of GH's hypothalamic precursor known as growth hormone releasing hormone (GHRH).
• Delta activity stimulates the release of several hormones, including growth hormone releasing hormone GHRH and prolactin (PRL).
• They release growth hormone (GH) in response to Growth hormone releasing hormone (GHRH, or somatocrinin) or are inhibited by GHIH (somatostatin), both received from the hypothalamus via the hypophyseal portal system vein and the secondary plexus.
• Such hypophysiotropic hormones include: CRF (corticotropin-releasing factor), GnRH (gonadotropin-releasing hormone), TRH (thyrotropin-releasing hormone), GHRH (growth hormone-releasing hormone), and DA (dopamine).
• Secretion is regulated by growth hormone-releasing hormone (GHRH) and growth hormone-inhibiting hormone (GHIH), or somatostatin.
• Growth hormone–releasing hormone (GHRH), also known as somatocrinin among other names in its endogenous form and as somatorelin (INN) in its pharmaceutical form, is a releasing hormone of growth hormone (GH).
• Growth hormone release hormone, or GHRH, is the key stimulator while somatostatin is the critical inhibitor of the synthesis and release of growth hormone.
• These pulses of GH are regulated by cells in the hypothalamus, via the release of growth hormone-releasing hormone (GHRH) into the hypothalamohypophysial system when stimulated by insulin, ghrelin, glucagon, arginine, deep sleep, exercise, fasting, sex hormone release during puberty, and a host of other factors.
• CJC-1295 DAC, also known as DAC:GRF (short for drug affinity complex:growth hormone-releasing factor), is a synthetic analogue of growth hormone-releasing hormone (GHRH) (also known as growth hormone-releasing factor (GRF)) and a growth hormone secretagogue (GHS) which was developed by ConjuChem Biotechnologies.
• Tesamorelin (INN) (trade name Egrifta SV) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy, approved initially in 2010.
• However, unlike pralmorelin (GHRP-2) and GHRP-6, but similarly to growth hormone-releasing hormone (GHRH), ipamorelin does not stimulate the secretion of adrenocorticotropic hormone (ACTH), or cortisol, and is highly selective for inducing the secretion only of GH.

Förberedelsen av sidan tog: 195,67 ms.